Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 27, Issue 15, p.2450-6 (2009)

Keywords:

2009, Adult, Aged, Aged, 80 and over, Anilides, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Estramustine, Goserelin, Humans, Male, Middle Aged, MITOXANTRONE, Nitriles, Prednisone, Prostate-Specific Antigen, Prostatic Neoplasms, Public Health Sciences Division, Taxoids, Tosyl Compounds, Tumor Markers, Biological

Abstract:

Prostate-specific antigen progression (PSA-P) is an indicator of progression in hormone-sensitive (HS) and castration-resistant (CR) prostate cancer (PC). We evaluated different definitions of PSA-P as predictors of overall survival (OS).